Fabio Borgonovo

Dr. Fabio Borgonovo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
FBFabio Borgonovo
Fabio Borgonovo
MQMassimiliano Quici
Massimiliano Quici
AGAntonio Gidaro
Antonio Gidaro
DGdavide giustivi
davide giustivi
DCDario Cattaneo
Dario Cattaneo
AFAntonella Foschi
Antonella Foschi
Most antimicrobial drugs need an intravenous (IV) administration to achieve maximum efficacy against target pathogens. IV administration is related to complications, such as tissue infiltration and thrombo-phlebitis. This systematic review aims to provide practical recommendations about diluent, pH, osmolarity, dosage, infusion rate, vesicant properties, and phlebitis rate of the most commonly used antimicrobial drugs evaluated in randomized controlled studies (RCT) till 31 March 2023. The authors searched for available IV antimicrobial drugs in RCT in PUBMED EMBASE®, EBSCO® CINAHL®, and the Cochrane Controlled Clinical trials. Drugs’ chemical features were searched online, in drug data sheets, and in scientific papers, establishing that the drugs with a pH of 9, osmolarity >600 mOsm/L, high incidence of phlebitis reported in the literature, and vesicant drugs need the adoption of utmost caution during administration. We evaluated 931 papers; 232 studies were included. A total of 82 antimicrobials were identified. Regarding antibiotics, 37 reach the “caution” criterion, as well as seven antivirals, 10 antifungals, and three antiprotozoals. In this subgroup of antimicrobials, the correct vascular access device (VAD) selection is essential to avoid complications due to the administration through a peripheral vein. Knowing the physicochemical characteristics of antimicrobials is crucial to improve the patient’s safety significantly, thus avoiding administration errors and local side effects.

Verified
Journal Article
Open access
PDF file
FPFlavia Pennisi
Flavia Pennisi
APAntonio Pinto
Antonio Pinto
FBFabio Borgonovo
Fabio Borgonovo
GSGiovanni Scaglione
Giovanni Scaglione
RLRiccardo Ligresti
Riccardo Ligresti
VGVincenza Gianfredi
Vincenza Gianfredi
Background: Mosquito-borne viral diseases are a growing global health threat, and artificial intelligence (AI) and machine learning (ML) are increasingly proposed as forecasting tools to support early-warning and response. However, the available evidence is fragmented across pathogens, settings and modelling approaches. This review provides, to the best of our knowledge, the first comprehensive comparative assessment of AI/ML models forecasting mosquito-borne viral diseases in human populations, jointly synthesising predictive performance across model families and appraising both methodological quality and operational readiness. Methods: Following PRISMA 2020, we searched PubMed, Embase and Scopus up to August 2025. We included studies applying AI/ML or statistical models to predict arboviral incidence, outbreaks or temporal trends and reporting at least one quantitative performance metric. Given the substantial heterogeneity in outcomes, predictors and time–space scales, we conducted a descriptive synthesis. Risk of bias and applicability were evaluated using PROBAST. Results: Ninety-eight studies met the inclusion criteria, of which 91 focused on dengue. The forecasts spanned national to city-level settings and annual-to-weekly resolutions. Across classification tasks, tree-ensemble models showed the most consistent performance, with accuracies typically above 0.85, while classical ML and deep-learning models showed wider variability. For regression tasks, errors increased with temporal horizon and spatial aggregation: short-term, fine-scale forecasts (e.g., weekly city level) often achieved low absolute errors, whereas long-horizon national models frequently exhibited very large errors and unstable performance. PROBAST assessment indicated that most studies (63/98) were at high risk of bias, with only 24 judged at low risk and limited external validation. Conclusions: AI/ML models, especially tree-ensemble approaches, show strong potential for short-term, fine-scale forecasting, but their reliability drops substantially at broader spatial and temporal scales. Most remain research-stage, with limited external validation and minimal operational deployment. This review clarifies current capabilities and highlights three priorities for real-world use: standardised reporting, rigorous external validation, and context-specific calibration.

6 August 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
GSGiovanni Scaglione
Giovanni Scaglione
MCMarta Colaneri
Marta Colaneri
MOMARTINA OFFER
MARTINA OFFER
LGLucia Galli
Lucia Galli
FBFabio Borgonovo
Fabio Borgonovo
AFAntonella Foschi
Antonella Foschi
Introduction: Vascular access devices (VADs), namely peripheral VADs (PVADs) and central venous VADs (CVADs), are crucial in both intensive care unit (ICU) and non-ICU settings. However, VAD placement carries risks, notably catheter-related bloodstream infections (CRBSIs). Candida spp. is a common pathogen in CRBSIs, yet its clinical and microbiological characteristics, especially in non-ICU settings, are underexplored. Methods: We conducted a monocentric, retrospective observational study at Luigi Sacco Hospital from 1 May 2021 to 1 September 2023. We reviewed medical records of non-ICU adult patients with CVADs and PVADs. Data on demographics, clinical and laboratory results, VAD placement, and CRBSI occurrences were collected. Statistical analysis compared Candida spp. CRBSI and bacterial CRBSI groups. Results: Out of 1802 VAD placements in 1518 patients, 54 cases of CRBSI were identified, and Candida spp. was isolated in 30.9% of episodes. The prevalence of CRBSI was 3.05%, with Candida spp. accounting for 0.94%. Incidence rates were 2.35 per 1000 catheter days for CRBSI, with Candida albicans and Candida non-albicans at 0.47 and 0.26 per 1000 catheter days, respectively—patients with Candida spp. CRBSI had more frequent SARS-CoV-2 infection, COVID-19 pneumonia, and hypoalbuminemia. Conclusions: During the COVID-19 pandemic, Candida spp. was a notable cause of CRBSIs in our center, underscoring the importance of considering Candida spp. in suspected CRBSI cases, including those in non-ICU settings and in those with PVADs.

4 February 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
TMTakahiro Matsuo
Takahiro Matsuo
FBFabio Borgonovo
Fabio Borgonovo
BLBrian D Lahr
Brian D Lahr
FPFrancesco Petri
Francesco Petri
RIRita Igwilo-Alaneme
Rita Igwilo-Alaneme
EBElie F. Berbari
Elie F. Berbari
Background: Native vertebral osteomyelitis (NVO) is a life-threatening spinal infection with rising incidence and significant morbidity. Despite its growing burden, long-term data on clinical characteristics, management trends, and outcomes remain limited. Methods: We conducted a 26-year multicenter retrospective cohort study of adults (≥18 years) diagnosed with NVO at Mayo Clinic sites between 1999 and 2024. Demographic, microbiologic, treatment, and outcome data were analyzed across five time periods. Predictors of treatment failure were assessed using a multivariable competing risk model. Results: Among 1255 patients (median age 67; 66% male), lumbosacral involvement was most common (65%), and 21% had multilevel involvement. Pathogens were identified in 77%, most commonly Staphylococcus aureus (49%; Methicillin-susceptible S. aureus 37%, methicillin-resistant S. aureus 13%). Over time from 1999–2004 to 2020–2024, Gram-negative bacilli increased from 6% to 14% (P = .048). Comorbidities including chronic kidney disease (10% to 21%), active chemotherapy (6% to 11%), and immunosuppression (8% to 17%) increased significantly. Additionally, 1-year treatment failure declined (16% to 10%). In multivariable analysis, diabetes mellitus (subdistribution hazard ratio [sHR] 1.92, 95% CI 1.18–3.13) and multilevel involvement (sHR 1.67, 95% CI 1.17–2.38) were associated with increased incidence of treatment failure, while concurrent infections (sHR 0.57, 95% CI 0.37–0.87) and higher Charlson Comorbidity Index (sHR 0.62, 95% CI 0.43–0.90) were associated with lower failure. Conclusions: This large multicenter cohort highlights increasing host complexity, shifting microbiology, and predictors of failure, emphasizing the importance of early risk stratification and tailored strategies, such as multidisciplinary evaluation and close follow-up of high-risk patients to improve outcomes.

23 May 2025 in Mayo Clinic Proceedings: Digital Health
Verified
Journal Article
Open access
FBFabio Borgonovo
Fabio Borgonovo
TMTakahiro Matsuo
Takahiro Matsuo
FPFrancesco Petri
Francesco Petri
SASeyed Mohammad Amin Alavi
Seyed Mohammad Amin Alavi
LNLaura Chelsea Mazudie Ndjonko
Laura Chelsea Mazudie Ndjonko
EBElie F. Berbari
Elie F. Berbari
To evaluate the ability of 15 different large language models (LLMs) to solve clinical cases with osteoarticular infections following published guidelines. The study evaluated 15 LLMs across 5 categories of osteoarticular infections: periprosthetic joint infection, diabetic foot infection, native vertebral osteomyelitis, fracture-related infections, and septic arthritis. Models were selected systematically, including general-purpose and medical-specific systems, ensuring robust English support. In total, 126 text-based questions, developed by the authors from published guidelines and validated by experts, assessed diagnostic, management, and treatment strategies. Each model answered individually, with responses classified as correct or incorrect based on guidelines. All tests were conducted between April 17, 2025, and April 28, 2025. Results, presented as percentages of correct answers and aggregated scores, highlight performance trends. Mixed-effects logistic regression with a random question effect was used to quantify how each LLM compared in answering the study questions. The performance of 15 LLMs was evaluated, with the percentage of correct answers reported. OpenEvidence and Microsoft Copilot achieved the highest score (119/126 [94.4%]), excelling in multiple categories. ChatGPT-4o and Gemini 2.5 Pro scored 117 of the 126 (92.8%). When used as references, OpenEvidence was not inferior to any comparator and was superior to 5 LLMs. Performance varied across categories, highlighting the strengths and limitations of individual models. OpenEvidence and Miccrosoft Copilot achieved the highest accuracy among evaluated LLMs, highlighting their potential for precisely addressing complex clinical cases. This study emphasizes the need for specialized, validated artificial intelligence tools in medical practice. Although promising, current models face limitations in real-world applications, requiring further refinement to support clinical decision making reliably.

3 September 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ACAmedeo F. Capetti
Amedeo F. Capetti
FBFabio Borgonovo
Fabio Borgonovo
VMValentina Morena
Valentina Morena
ALAngelica Lupo
Angelica Lupo
Maria Vittoria CossuMaria Vittoria Cossu
Maria Vittoria Cossu
GRGiuliano Rizzardini
Giuliano Rizzardini
Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.